Kolistimetatnatrium Noridem (Colistimethate Sodium)

Colistimethate sodium is converted in the body to colistin, which binds to the lipid A portion of bacterial lipopolysaccharide. This binding disrupts the outer membrane of Gram‑negative bacteria, increasing permeability and causing cell death.

The dosage of Kolistimetatnatrium Noridem is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and route of administration. Exact regimens are individualized and not publicly disclosed.

Safety data for colistimethate sodium in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kolistimetatnatrium Noridem delivers colistimethate sodium directly into the cerebrospinal fluid, offering higher local concentrations than systemic polymyxins. This route can be advantageous for CNS infections, whereas other polymyxins are typically given intravenously for systemic infections.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture and direct sunlight to maintain stability before reconstitution for intracerebroventricular or intrathecal administration.

Kolistimetatnatrium Noridem is supplied as a sterile powder for injection and must be reconstituted according to the manufacturer's instructions. It is then administered by a qualified healthcare professional via intracerebroventricular or intrathecal injection into the cerebrospinal fluid.

Serious risks include acute renal failure, severe allergic reactions such as anaphylaxis, neuromuscular blockade leading to respiratory compromise, and seizures. Patients should be closely monitored for these events, especially when receiving high doses or concomitant nephrotoxic drugs.

Patients with known hypersensitivity to colistimethate sodium or any component of the formulation should avoid this product. Caution is also advised for individuals with pre‑existing severe renal impairment, uncontrolled neuromuscular disorders, or those receiving interacting nephrotoxic or neuromuscular‑blocking agents.